GleamWall
中文EN

PRFX PRF Technologies Ltd. Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1801834 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY65.6%
TTM EPS YoY92.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin-311.8%
Operating margin-30,129.4%
Net margin-29,541.2%
FCF margin-23,276.5%
EBITDA margin-30,041.2%

Returns

ROE-96.9%
ROA-60.8%
ROIC (approx.)-271.5%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets22.6%
Debt / equity0.00x
Current ratio1.78x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-12.9%
Payout ratio—
Capex / revenue11.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$17,000$0$0——
Cost of revenue$70,000$0$0——
Gross profit-$53,000$0$0——
R&D expense$1.14M$11.71M$6.04M$4.42M$2.86M
SG&A expense$1.40M$1.32M$1.68M$2.09M$2.15M
Operating income-$5.12M-$14.67M-$9.58M-$8.87M-$7.21M
Pretax income-$5.01M-$14.58M-$9.34M-$8.78M-$7.24M
Income tax$8,000$8,000$8,000$9,000$6,000
Net income-$5.02M-$14.59M-$9.34M-$8.79M-$7.25M
EBITDA-$5.11M-$14.66M-$9.57M-$8.85M-$7.20M
EPS (basic)-7.47-105.52-122.94-63.46-7.25
EPS (diluted)-7.47-105.52-122.94-63.46-7.25
Weighted avg. shares (diluted)647,973138,25476,005138,548999,562
Banking
Net interest income———$0$0
Balance sheet
Cash & equivalents$3.12M$4.26M$8.03M$4.11M$16.57M
Short-term investments——$0$6.08M$0
Current assets$4.35M$4.43M$9.80M$12.28M$19.02M
PP&E, net$30,000$35,000$38,000$44,000$53,000
Goodwill$186,000$0———
Intangibles$7.41M$0———
Total assets$12.00M$4.53M$9.93M$12.33M$19.07M
Current liabilities$2.44M$2.44M$2.41M$1.06M$757,000
Total liabilities$2.71M$2.70M$2.69M$1.31M$991,000
Shareholders' equity$8.54M$1.82M$7.24M$11.02M$18.08M
Shares outstanding830,613341,827165,4891.08M10.48M
Cash flow statement
Operating cash flow-$3.96M-$12.62M-$6.68M-$6.46M-$6.55M
Capital expenditure$2,000$13,000$9,000$6,000$50,000
Free cash flow-$3.96M-$12.63M-$6.69M-$6.46M-$6.60M
Investing cash flow-$982,000-$13,000$5.99M-$6.01M-$50,000
Financing cash flow$3.82M$8.86M$4.62M$0$7.48M
Depreciation & amortization$15,000$16,000$15,000$15,000$7,000
Stock-based compensation$447,000$310,000$804,000$1.39M$812,000

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.